Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EXCIPIENT SAFETY GUIDELINES DEVELOPED BY INTERNATIONAL INDUSTRY GROUP

Executive Summary

EXCIPIENT SAFETY GUIDELINES DEVELOPED BY INTERNATIONAL INDUSTRY GROUP are being prepared for journal publication later this year. The International Pharmaceutical Excipients Council, a group composed of 100 companies worldwide which manufacture or use excipients, has composed guidelines for testing new drug excipients which may be published in Regulatory Pharmacology and Toxicology this summer. IPEC developed these guidelines as part of a strategy to expedite the review of new pharmaceutical excipients, council member Marshall Steinberg, PhD, Hercules VP-Health & Environment, explained at a seminar with FDA headquarters staff in mid-January. There are no regulatory guidelines available which specifically address the requirements for testing a material intended for use as a new excipient in pharmaceuticals, Steinberg pointed out. That situation has created a de facto limitation on the use of new excipients. Only materials which have been previously approved for use in a pharmaceutical product or which have been used in foods can safely be considered in the absence of testing procedures for new ingredients. The IPEC recommendations consist of "Universal Guidelines," which identify a series of tests to be performed to give a baseline set of data for all candidate compounds, and additional test requirements for specific routes of administration. The data requirements of the universal guidelines include a number of interim checkpoints which correlate with use of a proposed excipient in a particular type of drug product, i.e, a product with a short half-life, a product for limited repeated intake or a product to be taken chronically or chronically intermittently. Transdermal, topical, parenteral, inhaled or intranasal, and ophthalmic dosage forms all require additional steps at each stage of evaluation. IPEC developed the guidelines based upon "the best currently available toxicological science," according to a draft. Consideration was given to regulatory requirements as well as the deliberations of the International Conference on Harmonization. Following publication, IPEC will consider the comments it receives from the industry.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel